^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TSC1 deletion

    i
    Entrez ID:
    64930
    Related biomarkers:
    Mutation
    CNA
    Apply
    Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) (NCT04267120)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    11/26/2024
    Initiation :
    07/29/2020
    Primary completion :
    07/09/2024
    Completion :
    12/31/2025
    SDHB • TSC1
    |
    TSC1 deletion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)